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Background: Hyperuricemia appeared to be a common symptom in IgA nephropathy (IgAN), even in those with
normal eGFR. IgAN was characterized by variation of pathological features, especially variable tubulointerstitial
lesions. Since tubular reabsorption and excretion appeared to be more important in determination of plasma uric
acid levels in persons without obvious decrease of glomerular filtration rate, we took advantage of our IgAN cohort
to investigate whether plasma uric acid level associated with tubular interstitial lesions, and could be considered as
a maker for tubular interstitial lesions, especially at early stage with normal eGFR.
Methods: 623 IgAN patients were involved in the present study. Morphological changes were evaluated with
Oxford classification scoring system as well as Beijing classification system of IgAN. Statistical analysis was done with
SPSS 13.0.
Results: We found that plasma uric acid level associated with percentage of interstitial fibrosis/tubular atrophy.
Higher plasma uric acid levels indicated higher tubulointerstitial scores, either with Oxford system (P = 0.012) or
with Beijing classification system (P = 4.8*10-4) in the whole cohort. We also found that in the subgroup of 258 IgAN
cases with normal baseline eGFR (eGFR > =90 ml/min/1.73 M2), higher plasma uric acid associated with more severe
tubulointerstitial lesions with Beijing scoring system (P = 3.4*10-5). The risk of having more than 10% tubulointerstitial
lesions in patients with hyperuricemia increased 58% compared with normal uric acid level. In subgroup with normal
eGFR, only hyperuricemia predicted tubulointerstitial leisions, and the risk of having more tubulointerstitial changes
increased 100%. Among these patients, hyperuricemia was associated with more tubulointerstitial lesions with a specificity
of 60.3%. Specificity increased to 65% among those patients with eGFR > =90 ml/min/1.73 m2.
Conclusions: Plasma uric acid levels indicate tubular interstitial lesions in IgAN and hyperuricemia may be considered as
a marker for tubulointerstitial lesions.
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Hyperuricemia appeares to be a common manifestation in
IgA nephropathy (IgAN) patients, even when their glom-
erular filtration rate (GFR) are normal and hyperuricemia
has been considered as a risk factor of chronic kidney dis-
ease progression [1-4]. However, why plasma uric acid
level elevated in part of IgAN patients with young age and
normal GFR did not get enough attention.* Correspondence: cyq@bjmu.edu.cn
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reproduction in any medium, provided the orIt is well known that renal handling of uric acid ex-
cretion is a major denominator of plasma uric acid
levels in adults with hyperuricemia [5-7]. Renal uric
acid excretion is regulated by multiple factors such as
glomerular filtration rate, tubular re-absorption and
excretion [5,7]. Tubular reabsorption and excretion ap-
pear to be more important in determination of plasma
uric acid levels in persons without obvious decrease of
GFR.
IgAN is characterized by variation of pathological fea-
tures, especially variable tubulointerstitial lesions from
almost normal to diffuse tubular atrophy and interstitial
fibrosis [8], and tubulointerstitial damage has beentd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics of the IgAN corhort
N = 623 N = 258 (eGFR > =90 ml/
min/1.73 m2)
Age (years) 33.2 ± 0.5 28.8 ± 0.6
Male/Female (N) 342/281 120/138
BMI (kg/m2) 24.8 ± 0.3 22.9 ± 0.6
SBP (mmHg) 118.7 ± 0.7 115 ± 1.1
DBP (mmHg) 74.8 ± 0.6 72.6 ± 1.0
eGFR (ml/min/1.73 m2) 84.2 ± 1.4 112.9 ± 1.8
pCr (μmol/L) 108.0 ± 3.0 72.8 ± 0.8
pUA (μmol/L) 374.3 ± 4.4 338.2 ± 6.7
Hyperuricemia (Y/N) (%) 51.5/48.5 37.9/62.1
TC (mmol/L) 4.9 ± 0.1 4.7 ± 0.1
TG (mmo/L) 1.5 (1.0-2.3) 1.4 (0.8-2.2)
pNa+(mmol/L) 140.4 ± 0.2 139.8 ± 0.2
UP (g/24 h) 1.4 (0.7-1.6) 1.3 (0.6-2.3)
Oxford score [14,15]
M0/1 (%) 49/51 54/46
E0/1 (%) 69/31 69/31
S0/1 (%) 53/47 61/39
T0/1/2 (%) 79/10/11 95/3/2
Beijing score [16]






ACEi + ARB 42 42
Data were presented as Mean ± SEM or median (inter-quartile range [IQR]) for
continuous variables and proportions for categorical variables. SBP: Systolic
blood pressure; DBP: Diastolic blood pressure; UP: Urinary protein; pCr: Plasma
creatinine; pNa+: Plasma sodium; TC: Total cholesterol; TG: Triglyceride. ACEi:
Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker.
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of IgAN [9-12]. So we took advantage of our IgAN co-
hort to investigate whether plasma uric acid level associ-
ated with tubular interstitial lesions, and furthermore
could be considered as a maker for tubular/interstitial
lesions, especially at early stage with normal eGFR.
Methods
Subjects
623 individuals (342 males and 281 females), were ran-
domizely recruited from the IgA Nephropathy database
at Renal Division of Peking University First Hospital.
Among them, 258 individuals with estimated GFR
(eGFR) > = 90 ml/min/1.73 m2. Characteristics of the
population were listed in Table 1. eGFR was calculated
with the equation developed from data the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation [13].
The protocal for this study was approved by the Medi-
cial Ethics Committee of Peking University and informed
written consent for this study was obtained from every
participant.
Evaluation of renal pathological changes
Two pathologists re-evaluated the renal biopsy slides with
Oxford classification system of IgAN. Briefly, microscopic
slides of all cases were reviewed independently by each of
the pathologists. Histological parameters were evaluated
as: 1) Mesangial hypercellularity score (If more than half
the glomeruli have more than three cells in a mesangial
area, this is categorized as M1, otherwise as M0; M0 ≤ 0.5/
M1 > 0.5); 2) Endocapillary hypercellularity (hypercellu-
larity due to increased number of cells within glomerular
capillary lumina causing narrowing of the lumina, E0 as
absent/E1 as present); 3) Segmental glomerulosclerosis
(any amount of the tuft involved in sclerosis, but not in-
volving the whole tuft or the present of an adhesion, S0
means absent /S1 means present); 4) Interstitial fibrosis/
tubular atrophy (percentage of cortical area involved by
the tubular atrophy or interstitial fibrosis, T0: 0-25%/
T1: 26-50%/T2: >50%) [14,15]. Meanwhile, the histo-
logical changes of interstitial fibrosis/tubular atrophy
were also graded by Beijing classification system of
IgAN in present study (T0: 0%/T1: < 10%/T2: 10-24%/
T3:25-49%/T4: >= 50%) [16].
Statistical analyses
Statistical Package for the Social Sciences (SPSS v13.0;
Chicago, IL) was used. Baseline characteristics were re-
ported as mean ± SEM or median (inter-quartile range
[IQR]) for continuous variables and proportions for cat-
egorical variables. Association of plasma uric acid levels
and tubular atrophy/interstitial fibrosis was analyzed by
univariate analysis with covariates (age, gender, BMI,proteinuria, systolic blood pressure, diastolic blood
pressure and other pathological parameters) adjust-
ment. Correlation among plasma uric acid levels, eGFR
and tubulointerstitial lesions were analyzed with Spear-
man's correlation in the whole cohort and the subgroup
with different eGFR. Logistic regression was performed
to detect whether hyperuricemia was a predictor of
tubulointerstitial changes. In each Model, physical and
biochemical traits including age, gender, eGFR, urinary
protein, systolic blood pressure, diastolic blood pressure
and hyperuricemia were analyzed by single factor ana-
lysis first, and significant factors were put into multiple
factor model. Chi-square was used to calculate sensitiv-
ity and specificity of hyperuricemia prediction of tubu-
lointerstitial change.
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General data
General baseline data within one week before renal biopsy
were collected. Among the 623 IgAN, 258 cases presented
with normal eGFR (> = 90 ml/min/1.73 m2). The patho-
logical changes of all cases were evaluated with Oxford
classification system, and tubulointerstitial changes were re-
evaluated with Beijing classification system as well (Table 1).
Plasma uric acid levels associated with tubular atrophy
and interstitial fibrosis
We found that plasma uric acid level associated with
percentage of interstitial fibrosis/tubular atrophy. Higher
plasma uric acid levels indicated higher tubulointerstitial
scores, either with Oxford system (P = 0.012; Table 2) or
with Beijing system (P = 4.8*10-4; Table 2).
We did the same analyses in the subgroup of 258 IgAN
cases with normal baseline eGFR (eGFR > =90 ml/min/
1.73 M2, Table 2). With Beijing classification system we
also found that tubulointerstitial scores associated with
plasma uric acid levels in the subgroup of normal eGFR
(P = 3.4*10-5; Table 2), higher plasma uric acid associated
with more severe tubulointerstitial lesions.Table 2 Plasma uric acid levels associated with tubular atroph
The whole cohort Subg
PUA (μmol/L) P PUA
Oxford score
T0 (N = 494) 359.2+/−4.8 T0 (N
T1 (N = 59) 411.9+/−13.8 0.012 T1 (N




Tadj_Ox1 432.1+/−9.4 1.5*10-11 Tadj_
(N = 129)
Beijing score
T0 (N = 46) 340.9+/−15.5 T0 (N
T1 (N = 332) 351.9+/−5.8 T1 (N
T2 (N = 118) 387.0+/−9.7 4.8*10-4 T2 (N
T3 (N = 57) 413.7+/−13.9 T3 (N




Tadj_Bj1 411.0+/−6.8 0.004 Tadj_
(N = 245)
Data was presented as Mean ± SEM. Analyses were performed with univariate analy
atrophy/ interstitial fibrosis was analyzed as Oxford score, Beijing score separately, a
pathological items. Tadj_Ox: all individuals were re-attributed into two groups, acco
> 25%), or to 10% interstitial fibrosis/tubular atrophy (Tadj_Bj0 < 10%, Tadj_Bj1 >= 1In Beijing scoring system, tubular atrophy/interstitial
fibrosis more than 10% was identified as cut-off point of
higher risk for ESRD [16]. Similarly more than 25% of tubu-
lar atrophy/interstitial fibrosis also increased risk of GFR
decline in Oxford system. So here we re-attributed all
individuals into two groups, by 10% interstitial fibrosis/
tubular atrophy (Tadj_Bj0 < 10%, Tadj_Bi1 >= 10%), then by
25% interstitial fibrosis/tubular atrophy (Tadj_Ox0 < =25%,
Tadj_Ox1 > 25%) and re-analyzed the association of in-
terstitial fibrosis/tubular atrophy with plasma uric acid
level, both in the whole cohort and subgroup with nor-
mal eGFR. Again, tubulointerstitial changes divided by
25% or 10% interstitial fibrosis/tubular atrophy associ-
ated with plasma uric acid levels. Patients with more
tubular atrophy/interstitial fibrosis had higher plasma
uric acid level (Table 2).
Hyperuricemia as a clinical marker of tubular atrophy/
interstitial fibrosis
Since higher plasma uric acid levels associated with
more tubular atrophy/interstitial fibrosis, we further an-
alyzed whether hyperuricemia was a predictor of tubu-
lar atrophy/interstitial fibrosis in IgAN. It showed thaty/interstitial fibrosis in IgA nephropathy
roup (eGFR > =90 ml/min/1.73 m2) P
(μmol/L)
= 246) 335.9+/−6.9
= 8) 363.4+/−35.8 0.256
= 4) 416.7+/−53.7
Ox0 (N = 246) 335.9+/−6.9
Ox1 (N = 12) 349.8+/−2.8 0.150
= 34) 335.9+/−18.3
= 175) 328.5+/−8.1
= 37) 371.8+/−17.6 3.4*10-5
= 8) 363.8+/−37.8
= 4) 416.7+/−53.7
Bj0 (N = 209) 329.7+/−7.4
Bj1 (N = 49) 374.2+/−15.2 2.3*10-4
sis in the whole cohort and the subgroup. PUA: plasma uric acid. Tubular
nd adjusted by age, gender, BMI, eGFR, proteinuria, drug therapy and other
rding to 25% interstitial fibrosis/tubular atrophy (Tadj_Ox0 <= 25%, Tadj_Ox1
0%).
Table 4 Multivariate analysis for predictors of 10%
tubular atrophy/interstitial fibrosis in IgA nephropathy
Predictors OR 95%C.I. P
The whole cohort (N = 623)
eGFR 0.968 0.961-0.975 <0.001
HUA 1.585 1.091-2.303 0.016
Subgroup with eGFR > =90 ml/min/1.73 m2 (N = 258)
HUA 2.097 1.112-3.957 0.022
Subgroup with eGFR < 90 ml/min/1.73 m2 (N = 365)
eGFR 0.9578 0.944-0.969 <0.001
Analyses were performed with logistic regressions in the whole cohort and the
subgroup. Tubular atrophy/ interstitial fibrosis were analyzed as two groups,
less than 10% interstitial fibrosis/tubular atrophy or more than 10% lesion
(Tadj_Bj0 < 10%, Tadj_Bj1 >= 10%). In each Model, physical and biochemical
traits including age, gender, BMI, baseline-eGFR, baseline UP, SBP, DBP, drug
therapy and hyperuricemia status were analyzed by single factor analysis first,
and factors that were significant were then put into multiple factor model.
Result by multiple factor analysis was presented. HUA: hyperuricemia (male
>420 μmol/L, female >360 μmol/L); eGFR: estimated GFR.
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plasma uric acid levels, both in the whole group and the
subgroup with eGFR less than 90 ml/min. But in the
subgroup with higher eGFR (> = 90 ml/min), only
plasma uric acid level correlated with tubulointerstitial
score (Table 3). In the logistic multivariate analysis
model, variables assessed as potential predictors in-
cluded age, gender, blood pressure, BMI, proteinuria,
eGFR. A combined model of eGFR and hyperuricemia
status predicted tubular atrophy/interstitial fibrosis in
the whole cohort. The risk of having more than 10%
tubulointerstitial lesions in patients with hyperuricemia
increased 58% compared with normal uric acid level. In
subgroup with higher eGFR (> = 90 ml/min), only hy-
peruricemia predicted tubulointerstitial lesions, and the
risk of having more tubulointerstitial changes increased
100% (Table 4). However in the subgroup with GFR less
than 90 ml/min, decrease of eGFR is the main risk fac-
tor for tubulointerstitial lesions.
Among these patients, hyperuricemia associated with
more tubulointerstitial lesions with a specificity of
60.3%. Specificity increased to 65% among those patients
with eGFR > =90 ml/min/1.73 m2 (Table 5).
Discussion
Tubulointerstitial damage has been reported to be an
important risk factor for progression of IgAN [9-12].Table 3 Correlation among tubulointerstitial score and
plasma uric acid concentration in different eGFR groups
T Oxford score Tadj_Ox T Beijing score Tadj_Bj GFR
The whole cohort (N = 623)
GFR −0.473 −0.425 −0.513 −0.451
p <0.001 <0.001 <0.001 <0.001
PUA 0.262 0.257 0.284 0.261 −0.371
p <0.001 <0.001 <0.001 <0.001 <0.001
Subgroup with eGFR > =90 ml/min/1.73 m2 (N = 258)
GFR −0.082 0.031 −0.002 −0.031
p 0.187 0.625 0.979 0.618
PUA 0.102 0.052 0.133 0.162 −0.160
p 0.104 0.405 0.032 0.009 0.010
Subgroup with eGFR < 90 ml/min/1.73 m2 (N = 365)
GFR −0.490 −0.503 −0.493 −0.378
p <0.001 <0.001 <0.001 <0.001
PUA 0.234 0.240 0.243 0.199 −0.374
p <0.001 <0.001 <0.001 <0.001 <0.001
Analyses were performed with Spearman's correlation in the whole cohort and
the subgroup with different GFR. PUA: plasma uric acid. Tubular atrophy/
interstitial fibrosis was analyzed as Oxford score, Beijing score Tadj_Ox: all
individuals were re-attributed into two groups, according to 25% interstitial
fibrosis/tubular atrophy (Tadj_Ox0 < =25%, Tadj_Ox1 > 25%); Tadj_Bj: all
individuals were re-attributed to 10% interstitial fibrosis/tubular atrophy
(Tadj_Bj0 < 10%, Tadj_Bj1 >= 10%).Many IgAN patients have tubular atrophy and interstitial
fibrosis even with normal eGFR. And it appeared that
pathological examination was the only method to detect
renal tubulointerstitial lesions. Hyperuricemia has been
an interesting clinical symptom in IgAN patients and
considered to be associated with prognosis of the disease
[1,17,18]. As early as 1975, Berger et al. has reported
that 20-60% patients with gout also have mild to moder-
ate renal dysfunction [19]. Besides influence of glomeru-
lar filtration rate on elimination of uric acid, several
studies suggested that renal tubules play crucial roles in
the regulation of uric acid balance in the body [20,21].
Thus we systematically evaluated the pathological
changes of 623 individuals with IgAN by Oxford classifi-
cation system [14,15], as well as the classification for
tubulointerstitial changes in Beijing system [16] and
found that tubular atrophy/interstitial fibrosis associated
with plasma uric acid levels. The higher plasma uric acid
levels indicated higher tubulointerstitial scores. And we
also found similar association in the subgroup with nor-
mal eGFR. Finally, we identified that hyperuricemia
could be a marker to predict tubular atrophy/interstitial
fibrosis in IgAN, especially in those with normal eGFR.Table 5 Specificity and sensitivity for predicting tubular
atrophy/interstitial fibrosis by hyperuricemia in IgA
Nephropathy
Sensitivity Specificity P (Chi-square) P (Exact)
The whole cohort
HUA 62.0% 60.3% 4.9*10-8 5.5*10-8
The subgroup with normal eGFR (> = 90 ml/min/1.73 m2)
HUA 53% 65.1% 0.016 0.022
HUA: hyperuricemia.
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logical classification system, Oxford system [14,15] as
well as Beijing system [16] and did analysis in whole co-
hort of 623 IgAN patients, then in subgroup with eGFR
> =90 ml/min/1.73 m2 and subgroup with eGFR < 90 ml/
min. Our result showed that eGFR correlated with tubu-
lointerstitial score better than plasma uric acid levels in
the whole cohort and in the subgroup with eGFR less
than 90 ml/min. Lower eGFR correlated with severe
tubulointerstitial lesions. However in the subgroup with
eGFR > = 90 ml/min, eGFR did not correlate with tubu-
lointerstitial score anymore, only uric acid levels pre-
sented correlation with the scores. Previously published
reports also found that plasma uric acid correlated with
pathological changes in 202 cases of IgAN, in which the
best correlation coefficients were 0.42 for interstitial fi-
brosis and 0.39 for tubular atrophy [17]. Although our
study did not identified such high correlation coeffi-
cients for plasma uric acid and tubulointerstitial lesions,
we found that plasma uric acid but not eGFR was an fac-
tor associated with tubulointerstitial changes in patients
with obviously normal eGFR. However when eGFR de-
creased, eGFR itself may be correlating with tubulointer-
stitial changes.
Since tubular atrophy/interstitial fibrosis more than
10% was identified as cut-off point of higher risk for
ESRD in Beijing scoring system [16] and more than 25%
tubular atrophy/interstitial fibrosis increased risk of GFR
decline in Oxford system, we collapsed individuals into
two groups by cut-off point at 10% for Beijing scoring
system, then by 25% interstitial fibrosis/tubular atrophy
for Oxford scoring system. We set up two models of
multivariate logistic regression, in which dependent vari-
able was tubulointerstitial lesion by 10% cut off in model
1 and tubulointerstitial lesion by 25% cut off in model 2.
For model 1, the risk of having more than 10% tubuloin-
terstitial lesions in IgAN patients with hyperuricemia in-
creased compared with normouricemia in whole cohort
as well as in subgroup with normal eGFR. For model 2,
none of the clinical signs predicted tubulointerstitial
changes. These may be explained by the time of renal bi-
opsy. Most patients accepted renal biopsy were attrib-
uted to less than 25% tubulointerstital lesions group,
especially those with normal eGFR.
Our study showed that hyperuricemia has specificity
of 60-64% to be associated with tubulointerstitial lesions
in IgAN. Although it is much less than accepted levels
of specificity 80% to consider hyperuricemia a predictor
for tubulointerstitial lesions, the specificity still indicated
the close association of hyperuricemia with tubulointer-
stitial score.
In summary, this observation study at an IgAN cohort
revealed that interstitial fibrosis/tubular atrophy was
associated with plasma uric acid levels in IgAN andplasma uric acid level was a hopeful clinical marker indi-
cating tubulointerstitial lesions especially in patients
with normal eGFR.
Conclusions
Hyepruricemia appeared to be a common symptom in
IgA nephropathy. We took advantage of our IgAN cohort
and found that plasma uric acid level indicates tubuloin-
terstitial lesions in IgAN and hyperuricemia may be con-
sidered as a marker for tubulointerstitial lesions.
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